TY  - JOUR
A1  - Untch, Michael
A1  - Konecny, Gottfried E.
A1  - Paepke, Stefan
A1  - Minckwitz, Gunter von
T1  - Current and future role of neoadjuvant therapy for breast cancer
T2  - The Breast
N2  - Neoadjuvant systemic chemotherapy is a possible therapeutic approach for the treatment of locally advanced operable, primarily non-operable or inflammatory breast cancer. Neoadjuvant systemic chemotherapy is an option for breast cancer patients who would require adjuvant chemotherapy otherwise based on clinical and histological examination and imaging. The use of neoadjuvant systemic therapy in operable breast cancer is currently increasing because of its advantages that include higher rates of breast conserving surgery and the possibility of measuring early in-vivo response to systemic treatment. The timing of axillary sentinel lymph node diagnosis (i.e. before or after neoadjuvant chemotherapy) is critical in that it may influence the likelihood of axillary preservation. It is not yet clear if neoadjuvant therapy might improve outcomes in certain subgroups of breast cancer patients. Neoadjuvant treatment modalities require a close collaboration between oncology professionals, including surgeons, gynecologists, medical oncologists, radiation oncologists, radiologists and pathologists. The most important parameter for treatment success and improved overall survival is the achievement of a pathologic complete response (pCR), although the role of pCR in patients with luminal A like tumours might be less informative. Identification of patient subgroups with high pCR rates may allow less invasive surgical or radiological interventions. Patients not achieving a pCR may be candidates for postoperative clinical trials exploring novel systemic treatments.
KW  - Breast cancer
KW  - Molecular subtypes
KW  - Neoadjuvant systemic therapy
KW  - Pathologic complete response
KW  - Breast conserving surgery
Y1  - 2014
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/77054
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-770548
SN  - 0960-9776
VL  - 23
IS  - 5
SP  - 526
EP  - 537
PB  - Elsevier
CY  - Amsterdam
ER  -